Bygbjerg I C, Flachs H
Eur J Clin Pharmacol. 1986;30(2):249-51. doi: 10.1007/BF00614314.
In vitro studies have indicated that the antifolates pyrimethamine [4, 6] and cycloguanil (the active metabolite of proguanil) suppress the proliferation of stimulated human lymphocytes; proguanil has no effect [2]. During the early growth phase of the cells, 14C-thymidine (14C-TdR) incorporation is increased by pyrimethamine and cycloguanil, reflecting blockage of endogenous TdR synthesis [3]. Proguanil (Paludrine) is increasingly being used for malaria prophylaxis. It is considered the most innocuous of the antimalarials currently employed. Since nothing is known about the effect of oral proguanil on human lymphocytes, the present study was undertaken. Little information is available about the serum levels of proguanil and cycloguanil following ingestion of prophylactic doses [8]. Therefore, the serum concentrations of proguanil and cycloguanil were estimated, to allow comparison with previous in vitro studies [2].
体外研究表明,抗叶酸药物乙胺嘧啶[4,6]和环氯胍(氯胍的活性代谢产物)可抑制人淋巴细胞的增殖;氯胍则无此作用[2]。在细胞生长早期,乙胺嘧啶和环氯胍可增加14C-胸腺嘧啶核苷(14C-TdR)的掺入,这反映了内源性TdR合成受阻[3]。氯胍(百乐君)越来越多地用于疟疾预防。它被认为是目前使用的抗疟药物中最无害的一种。由于对口服氯胍对人淋巴细胞的影响尚无了解,因此开展了本研究。关于摄入预防剂量后氯胍和环氯胍的血清水平,目前所知甚少[8]。因此,对氯胍和环氯胍的血清浓度进行了测定,以便与之前的体外研究[2]进行比较。